These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 26908801)

  • 1. Effect of Previous-Year Vaccination on the Efficacy, Immunogenicity, and Safety of High-Dose Inactivated Influenza Vaccine in Older Adults.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Clin Infect Dis; 2016 May; 62(9):1092-1099. PubMed ID: 26908801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty.
    DiazGranados CA; Dunning AJ; Robertson CA; Talbot HK; Landolfi V; Greenberg DP
    Vaccine; 2015 Aug; 33(36):4565-71. PubMed ID: 26187260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
    DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
    Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season.
    DiazGranados CA; Dunning AJ; Jordanov E; Landolfi V; Denis M; Talbot HK
    Vaccine; 2013 Jan; 31(6):861-6. PubMed ID: 23261045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of high-dose versus standard-dose influenza vaccine in older adults.
    DiazGranados CA; Dunning AJ; Kimmel M; Kirby D; Treanor J; Collins A; Pollak R; Christoff J; Earl J; Landolfi V; Martin E; Gurunathan S; Nathan R; Greenberg DP; Tornieporth NG; Decker MD; Talbot HK
    N Engl J Med; 2014 Aug; 371(7):635-45. PubMed ID: 25119609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy.
    Gilbert PB; Fong Y; Juraska M; Carpp LN; Monto AS; Martin ET; Petrie JG
    BMC Infect Dis; 2019 May; 19(1):453. PubMed ID: 31117986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.
    Gaglani M; Kim SS; Naleway AL; Levine MZ; Edwards L; Murthy K; Dunnigan K; Zunie T; Groom H; Ball S; Jeddy Z; Hunt D; Wesley MG; Sambhara S; Gangappa S; Grant L; Cao W; Gross FL; Mishina M; Fry AM; Thompson MG; Dawood FS; Flannery B
    Clin Infect Dis; 2023 Feb; 76(3):e1168-e1176. PubMed ID: 36031405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S; Nicolas JF; Szymanski H; Leroux-Roels I; Schaum T; Bonten M; Icardi G; Shrestha A; Tabar C;
    Hum Vaccin Immunother; 2021 Dec; 17(12):5475-5486. PubMed ID: 34714720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 dose-sparing, randomized clinical trial of seasonal trivalent inactivated influenza vaccine combined with MAS-1, a novel water-in-oil adjuvant/delivery system.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Feb; 40(9):1271-1281. PubMed ID: 35125219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older.
    Falsey AR; Treanor JJ; Tornieporth N; Capellan J; Gorse GJ
    J Infect Dis; 2009 Jul; 200(2):172-80. PubMed ID: 19508159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial.
    Jamshed S; Walsh EE; Dimitroff LJ; Santelli JS; Falsey AR
    Vaccine; 2016 Jan; 34(5):630-635. PubMed ID: 26721330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
    DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
    Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
    Becker DL; Chit A; DiazGranados CA; Maschio M; Yau E; Drummond M
    Hum Vaccin Immunother; 2016 Dec; 12(12):3036-3042. PubMed ID: 27669017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative and Absolute Effectiveness of High-Dose and Standard-Dose Influenza Vaccine Against Influenza-Related Hospitalization Among Older Adults-United States, 2015-2017.
    Doyle JD; Beacham L; Martin ET; Talbot HK; Monto A; Gaglani M; Middleton DB; Silveira FP; Zimmerman RK; Alyanak E; Smith ER; Flannery BL; Rolfes M; Ferdinands JM
    Clin Infect Dis; 2021 Mar; 72(6):995-1003. PubMed ID: 32067049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly.
    Gorse GJ; Grimes S; Buck H; Mulla H; White P; Hill H; May J; Frey SE; Blackburn P
    Vaccine; 2022 Mar; 40(10):1472-1482. PubMed ID: 35125224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
    Petrie JG; Ohmit SE; Truscon R; Johnson E; Braun TM; Levine MZ; Eichelberger MC; Monto AS
    J Infect Dis; 2016 Oct; 214(8):1142-9. PubMed ID: 27095420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.
    Comber L; O Murchu E; Jordan K; Hawkshaw S; Marshall L; O'Neill M; Teljeur C; Ryan M; Carnahan A; Pérez Martín JJ; Robertson AH; Johansen K; de Jonge J; Krause T; Nicolay N; Nohynek H; Pavlopoulou I; Pebody R; Penttinen P; Soler-Soneira M; Wichmann O; Harrington P
    Rev Med Virol; 2023 May; 33(3):e2330. PubMed ID: 35119149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
    Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
    Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of high-dose trivalent inactivated influenza vaccine compared to standard-dose vaccine in children and young adults with cancer or HIV infection.
    Hakim H; Allison KJ; Van de Velde LA; Tang L; Sun Y; Flynn PM; McCullers JA
    Vaccine; 2016 Jun; 34(27):3141-3148. PubMed ID: 27129426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.